SAN DIEGO—Jan De Witte, a director at ResMed Inc . (NYSE:), recently sold 796 shares of the company’s common stock. The shares were sold on November 12 at a price of $248.81 each, totaling approximately $198,052. Following this transaction, De Witte retains ownership of 6,723 shares in the company.
The sale was executed under a pre-established Rule 10b5-1 trading plan, which De Witte adopted on February 2, 2024. These plans allow company insiders to set up a predetermined schedule for selling stocks, aiming to avoid any accusations of insider trading.
In other recent news, ResMed reported a notable 11% increase in revenue and a 27% rise in operating profit in their Q1 Fiscal Year 2025 Earnings Call. This growth was attributed to strong demand for the company’s sleep and respiratory health devices, specifically the AirSense 10 and 11 platforms. ResMed also announced the forthcoming launch of the AirTouch N30i mask, expected to boost patient adherence thanks to its enhanced comfort.
As part of its growth strategy, ResMed plans to further its expansion into digital health and adjacent markets, focusing on innovation and strategic acquisitions to reinforce its global market position. The company is also leveraging macro trends and digital health innovations to penetrate markets like insomnia and COPD.
Despite some supply chain challenges and increased competition, particularly from Philips, ResMed remains confident in maintaining its market position. The company’s strategic acquisitions, such as Somnoware, are intended to enhance digital sleep health offerings and promote earlier engagement with pulmonary doctors. These are the latest developments in ResMed’s ongoing efforts to empower over 500 million people with its health tech solutions by 2030.
InvestingPro Insights
While Jan De Witte’s recent stock sale might raise eyebrows, a closer look at ResMed’s financial metrics and market position reveals a company with solid fundamentals. According to InvestingPro data, ResMed boasts a market capitalization of $34.37 billion, reflecting its significant presence in the medical devices industry.
The company’s financial health is underscored by its revenue growth, with a 9.88% increase over the last twelve months, reaching $4.81 billion. This growth trajectory is further supported by a robust gross profit margin of 58.33%, indicating efficient cost management and pricing power in its market segments.
InvestingPro Tips highlight ResMed’s commitment to shareholder returns, noting that the company has raised its dividend for 13 consecutive years. This consistent dividend growth, coupled with a current yield of 0.9%, suggests a balance between reinvesting in the business and rewarding shareholders.
Moreover, ResMed’s stock has demonstrated impressive performance, with a one-year price total return of 61.32%. This substantial gain aligns with another InvestingPro Tip indicating high returns over the last year, potentially justifying the company’s relatively high P/E ratio of 30.98.
For investors seeking a deeper understanding of ResMed’s potential, InvestingPro offers 14 additional tips, providing a comprehensive analysis of the company’s strengths and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
